Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies
Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: 421-424.e2. PMID: 33583730, DOI: 10.1016/j.clml.2021.01.010.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCombined Modality TherapyDisease ManagementDisease SusceptibilityDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsLeukemia, MyeloidMolecular Targeted TherapyMyeloproliferative DisordersPrognosisRetreatmentTreatment FailureTreatment Outcome